New price reductions for GSK antiretrovirals in the world's poorest countries

GlaxoSmithKlineGSK today announced significant new price reductions for its HIV medicines offered on a not-for-profit basis to the world's poorest countries. This reduction is the fifth time the company has made a price reduction as part of its pioneering preferential pricing policy originally introduced in 1997.

The price reductions will apply across the range of GSK's antiretrovirals offered at not-for-profit prices. The most significant reduction, of almost 40 per cent, will be on Ziagen oral solution (abacavir), which is recommended by the World Health Organization (WHO) for use in first-line and second-line regimens within resource-limited settings, particularly for children. The average reduction across GSK’s 14 not-for-profit HIV medicines is 21 per cent. These prices will take effect immediately for public sector customers and not-for-profit organisations in all the Least Developed Countries and Sub-Saharan Africa, as well as countries with eligible Global Fund and PEPFAR projects.

A number of factors have enabled GSK to implement these price changes, including improvements and efficiencies in manufacturing and supply, and reductions in the costs of active ingredients. These latest prices have been calculated based on the cost incurred by GSK, and savings realised are reflected in the new prices and passed on directly to purchasers. The prices include insurance and freight and are applicable to orders of any size and are not dependent on quantity.

JP Garnier, CEO GlaxoSmithKline said: "I have seen for myself the devastating impact of HIV/AIDS, and the continued response of the global community to this epidemic is vital. This further reduction in pricing of our HIV medicines demonstrates GSK's ongoing commitment to patients in the world's poorest countries. We also continue to focus on the research and development of new medicines and vaccines, and to build partnerships with others to help improve access and investment in communities."

About GlaxoSmithKline
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...